Teresa Lambe Selected Research

ChAdOx1 nCoV-19

11/2022	Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6-17 years: a preliminary report of COV006, a phase 2 single-blind, randomised, controlled trial.
7/2022	An exploratory analysis of the response to ChAdOx1 nCoV-19 (AZD1222) vaccine in males and females.
1/2022	CMV-associated T cell and NK cell terminal differentiation does not affect immunogenicity of ChAdOx1 vaccination.
12/2021	Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial.
11/2021	AZD1222/ChAdOx1 nCoV-19 vaccination induces a polyfunctional spike protein-specific TH1 response with a diverse TCR repertoire.
10/2021	ChAdOx1 nCoV-19 (AZD1222) protects Syrian hamsters against SARS-CoV-2 B.1.351 and B.1.1.7.
10/2021	Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil.
10/2021	Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial.
7/2021	T-cell mediated immunity after AZD1222 vaccination: A polyfunctional spike-specific Th1 response with a diverse TCR repertoire.
6/2021	ChAdOx1 nCoV-19 (AZD1222) protects Syrian hamsters against SARS-CoV-2 B.1.351 and B.1.1.7.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Teresa Lambe Research Topics

Disease

25	COVID-19 11/2022 - 01/2020
22	Infections 01/2022 - 06/2012
18	Human Influenza (Influenza) 01/2021 - 01/2011
9	Pneumonia (Pneumonitis) 10/2021 - 01/2020
5	Fever (Fevers) 11/2022 - 05/2020
5	Vaccinia 01/2020 - 03/2016
4	Pain (Aches) 11/2022 - 01/2020
3	Communicable Diseases (Infectious Diseases) 01/2022 - 12/2017
3	Lassa Fever (Fever, Lassa) 03/2021 - 12/2017
3	Autoimmune Diseases (Autoimmune Disease) 10/2007 - 09/2006
2	Asymptomatic Infections 01/2022 - 11/2021
2	Headache (Headaches) 12/2021 - 01/2020
2	Dyspnea (Shortness of Breath) 10/2021 - 01/2021
2	Cough 10/2021 - 01/2021
2	Ageusia (Hypogeusia) 10/2021 - 01/2021
2	Anosmia 10/2021 - 01/2021
2	Malaria 01/2017 - 01/2016
2	Virus Diseases (Viral Diseases) 10/2012 - 12/2011
1	Fatigue 01/2022
1	Breakthrough Infections 01/2022
1	Disease Progression 01/2022
1	HIV Infections (HIV Infection) 01/2021
1	Critical Illness (Critically Ill) 01/2021
1	Chills 01/2020
1	Prostatic Neoplasms (Prostate Cancer) 12/2017
1	Ebola Hemorrhagic Fever 05/2017
1	Vesicular Stomatitis 04/2016
1	Tuberculosis (Tuberculoses) 01/2016
1	Bacterial Infections (Bacterial Infection) 09/2013
1	Neoplasms (Cancer) 09/2013
1	Lymphoma (Lymphomas) 09/2013
1	Eczema 09/2013
1	hypochromic microcytic Anemia 02/2009
1	Iron-Deficiency Anemia (Anemia, Iron Deficiency) 02/2009
1	Glomerulonephritis 10/2007
1	MYD88 Deficiency 10/2007
1	Blindness (Hysterical Blindness) 04/2007
1	Uveomeningoencephalitic Syndrome (Vogt Koyanagi Harada Syndrome) 09/2006
1	Vitiligo 09/2006
1	Hypersensitivity (Allergy) 11/2004
1	Respiratory Hypersensitivity 11/2004
1	Parasitic Diseases (Parasitic Disease) 11/2004

Drug/Important Bio-Agent (IBA)

50	VaccinesIBA 07/2022 - 01/2011
21	ChAdOx1 nCoV-19IBA 11/2022 - 01/2020
14	Proteins (Proteins, Gene)FDA Link 01/2022 - 03/2002
9	AntigensIBA 01/2022 - 11/2004
9	Influenza Vaccines (Influenza Vaccine)FDA Link 01/2021 - 06/2012
8	AntibodiesIBA 01/2022 - 10/2007
8	NucleoproteinsIBA 01/2022 - 06/2012
4	Nucleic AcidsIBA 07/2022 - 01/2021
3	Antiviral Agents (Antivirals)IBA 10/2022 - 06/2016
3	Immunoglobulin G (IgG)IBA 01/2022 - 10/2007
3	COVID-19 VaccinesIBA 01/2022 - 01/2021
3	Neutralizing AntibodiesIBA 01/2021 - 04/2016
3	CytokinesIBA 06/2016 - 10/2007
3	Hemagglutinins (Hemagglutinin)IBA 06/2016 - 09/2012
2	EpitopesIBA 01/2022 - 01/2018
2	Messenger RNA (mRNA)IBA 01/2022 - 01/2022
2	MenACWYIBA 10/2021 - 01/2020
2	Glycoproteins (Glycoprotein)IBA 04/2016 - 09/2012
2	Immunoglobulin E (IgE)IBA 09/2013 - 11/2004
1	Meningococcal Vaccines (Meningococcal Vaccine)IBA 11/2022
1	N-(2-cyanoethylene)urea (BA 1)IBA 01/2022
1	SARS-CoV-2 spike proteinIBA 01/2022
1	N-methyl-valyl-amiclenomycin (BA 2)IBA 01/2022
1	2019-nCoV Vaccine mRNA-1273IBA 01/2022
1	BNT162 VaccineIBA 01/2022
1	sinovac COVID-19 vaccineIBA 01/2022
1	Biomarkers (Surrogate Marker)IBA 11/2021
1	P-2 (P 2)IBA 10/2021
1	Neuraminidase (Sialidase)IBA 01/2021
1	Alanine (L-Alanine)FDA Link 01/2021
1	Monoclonal AntibodiesIBA 01/2021
1	Viral AntigensIBA 01/2021
1	RNA (Ribonucleic Acid)IBA 01/2021
1	Blood Proteins (Serum Proteins)IBA 01/2021
1	Acetaminophen (Paracetamol)FDA LinkGeneric 01/2020
1	Ebola VaccinesIBA 01/2020
1	Middle East respiratory syndrome vaccineIBA 01/2017
1	Surface Antigens (Surface Antigen)IBA 04/2015
1	Complement Factor B (Factor B)IBA 09/2013
1	IntegrinsIBA 09/2013
1	Lymphocyte Function-Associated Antigen-1 (LFA-1)IBA 09/2013
1	Interferon-gamma (Interferon, gamma)IBA 06/2012
1	EnzymesIBA 06/2012
1	ImmunosorbentsIBA 06/2012
1	Guanine Nucleotide Exchange Factors (Guanine Nucleotide Exchange Factor)IBA 12/2011
1	IronIBA 02/2009
1	ferric citrate iron reductase (ferric-chelate reductase)IBA 02/2009
1	LigandsIBA 10/2007
1	Interleukin-6 (Interleukin 6)IBA 10/2007
1	Interleukin-12 (IL 12)IBA 10/2007
1	Retinaldehyde (Retinal)IBA 04/2007
1	Fas Ligand Protein (Fas Ligand)IBA 09/2006
1	hen egg lysozymeIBA 09/2006
1	Protein Kinase CIBA 03/2002

Therapy/Procedure

2	Intranasal Administration 09/2012 - 07/2012
1	Therapeutics 01/2022
1	Euthanasia (Mercy Killing) 03/2021
1	Intramuscular Injections 01/2020